A Brief Review on the Role of Vesicular Monoamine Transporter, Inhibitors in Hyperkinetic Movement Disorders

How to Cite This Article: Nikkhah A. A Brief Review on the Role of Vesicular Monoamine Transporter, Inhibitors in Hyperkinetic Movement Disorders. Iran J Child Neurol. Summer 2021; 15(3): 29-33

Abstract

Hyperkinetic movement disorders are a common group of movement abnormalities in children, characterized with repetitive unintended involuntary movements. Major hyperkinetic movements include tremor, tic, dystonia, myoclonus, and chorea. Although a number of drugs have been proven to be beneficial for these abnormalities, some patients may become resistant to conventional treatments. Vesicular monoamine transporter (VMAT₂) inhibitors (Tetrabenazine, Deutetrabenazine, and Valbenazine) are new agents introduced in the last decade for treating some of movement disorders, in particular tardive dyskinesia, Huntington chorea, and Tourette syndrome. In this brief review, we discussed the role of these drugs in managing hyperkinetic movement disorders.

Keywords: Vesicular monoamine transporter (VMAT₂) inhibitors; Hyperkinetic movements; Dyskinesia; Tetrabenazine; Deutetrabenazine; Valbenazine; Children.

DOI: 10.22037/ijcn.v15i3.33144

Introduction

Hyperkinetic movement disorders, which are characterized with repetitive unintended involuntary movements, encompass a variety of abnormal movements including tremor, tic, dystonia, myoclonus, and chorea in children (1). Symptomatic children are often treated with conventional drugs. For example, levodopa is an effective agent for some types of dystonia such as dopa responsive dystonia (DRD) (1, 2). However, some patients may fail to appropriately respond to traditional therapeutics. In addition to primary abnormal movements, some children may develop secondary movement disorders due to brain injury, encephalitis, and drugs/toxins. Considering that many of hyperkinetic movement disorders are secondary to a hyper-dopaminergic state in basal ganglia,
blocking dopamine receptors by neuroleptics is the most effective and first-line therapy in these conditions. However, these drugs have potentially serious side effects such as Tardive dyskinesia (TD) (3) which is a rare permanent movement disorder due to the prolonged use of dopamine receptor blockers, especially neuroleptics (4). This disorder presents with involuntary movements of the face and tongue, such as continuous chewing and tongue protrusion or thrust, along with choreiform movements of extremities (5).

Vesicular monoamine transporter 2 (VMAT₂) is a protein that transports monoamines (especially dopamine) into vesicles in presynaptic neurons (Fig 1).

In the last decade, VMAT₂ inhibitors (tetrabenazine, Deutetrabenazine, and valbenazine) were presented as a new class of drugs with beneficial effects in the treatment of movement disorders. In 2008, tetrabenazine was approved by the FDA for managing chorea in patients with Huntington disease (HD) (6, 7). There are two types of these transporters: VMAT1, which is present in both the peripheral and central nervous systems, and VMAT2, which has been localized only in presynaptic neurons (8) Also, tetrabenazine has been used as an off-label medication for treating Tourette’s disorder and TD (4). There are a few studies on the application of VMAT₂ inhibitors in children with hyperkinetic movement disorders. In this brief review, we intend to describe these new drugs and discuss their roles in treating hyperkinetic movement disorders in pediatrics.

**Drug Description**

**Tetrabenazine (TBZ)** was initially introduced in the 1950s as an antipsychotic agent (6). This drug was the first VMAT₂ inhibitor approved by the FDA in 2008 to treat HD-induced chorea (7, 8). Tetrabenazine binds to type 2 vesicular monoamine transporters (VMAT₂) and inhibits the entry of dopamine molecules into these vesicles, depleting their dopamine content. So, the drug is also known as a dopamine depletion agent. The VMAT-2 is found mainly in the central nervous system and transports serotonin, dopamine, norepinephrine, and histamine into vesicles for storage. Tetrabenazine depletes dopamine more selectively compared to other monoamines (9, 10).

In the liver, the drug is extensively metabolized to its primary active metabolite (alpha-dihydrotetrabenazine) by the CYP2D6 enzyme. The half-life of alpha-dihydrotetrabenazine is three to eight hours (11, 12). At high doses, TBZ also blocks postsynaptic dopamine receptors (i.e., a dopamine receptor blocker (DRB)) (8). This drug is an oral benzoquinoline derivative and is generally considered to be well-tolerated (13). In different studies, TBZ has been noted to be highly effective for treating HD-associated chorea (13-15). Also, this drug has been effective in the treatment of some other hyperkinetic movement disorders such as tics and dystonia. Tetrabenazine is also used to control motor and phonic tics in children and adolescents with Tourette syndrome (TS). In a relatively old
study on ten cases with TS, four patients receiving TBZ showed marked improvement in their tics, and the most common side effect was drowsiness (16). Unfortunately, to date, there is no randomized clinical trial on the efficacy and safety of TBZ in children. The initial dose is 12.5 mg/d which can be then adjusted to 12.5 mg/d every week at the maximum dose of 100 mg/d. Because of its short half-life, TBZ should be given two to three times a day after increasing the dose (11, 12, 14, 15). The most common adverse effects of TBZ in adults are somnolence, mood disorders, and Parkinsonism (14, 17). Drug-induced Parkinson disease is an important side effect limiting the use of TBZ and other similar drugs. Some rare adverse effects of TBZ include transient increased liver enzymes, insomnia, nausea, vomiting, tremor, memory problems, confusion, orthostatic hypotension, dizziness, diarrhea, headaches, hallucinations, paresthesia, pharyngeal spasm and pain, blurred vision, paranoia, and suicide (5, 8, 18). Since 2017, two newer VMAT$_2$ inhibitors have been approved by the FDA for managing some hyperkinetic movement disorders such as chorea (especially in patients with HD) and tics (especially in those suffering from TS) (8, 19, 20).

**Deutetrabenazine (DBZ)** was the first novel medication categorized under VMAT$_2$ inhibitors. A chemical substance in DBZ, named deuterium, reduces the drug’s metabolic rate and thus increases its half-life. Deutetrabenazine is an isotopic isomer of TBZ, resulting from the replacement of two methoxy groups (–OCH$_3$) with two trideuteromethoxy groups (–OCD$_3$) at the 9 and 10 positions, which reduces the side effects of DBZ (21). On the other hand, lower serum level fluctuations of this drug reduce its neuropsychiatric side effects such as depression and akathisia (19, 21, 22). Deutetrabenazine is an effective and safe VMAT$_2$ inhibitor for treating tardive dyskinesia and HD in adults and adolescents (23). In one open-label trial, DBZ at the doses of 18 to 36 mg/day decreased the severity of tics in adolescents with TS. Irritability, fatigue, and headache were reported as the side effects of DBZ in this study (24).

Valbenazine (VBZ) is the second (after DBZ) new VMAT$_2$ inhibitor approved by the FDA since 2017. This drug is an Alpha isomer of TBZ with an adequately long half-life (15-22 hr.) allowing it to be used once daily. The drug is activated by hydrolysis while its deactivation is catalyzed by CYP3A and CYP2D6 in the liver (23). The most common adverse effects of VBZ are sedation, anticholinergic effects, balance disorder, and headache (25). In contrast to TBZ and even DBZ, VBZ has not been associated with increased risk of suicidal thinking and behaviors in adults (27). However, VBZ may increase the QT interval, so it is not recommended to be used by patients with prolonged QT intervals (28). Some randomized clinical trials were conducted on the efficacy and safety of VBZ in adult patients with tardive dyskinesia; almost all of them reported improvements in dyskinetic movements (20). Recently, these drugs, as a second-line option after clonidine, have been used for managing TS. Today, VMAT2 inhibitors are superior to neuroleptics for controlling chronic and severe tics (29, 30).

**In Conclusion**

As mentioned above, VMAT$_2$ inhibitors are promising medications for some hyperkinetic movement disorders such as chorea (especially in HD), tics (in TS), and tardive dyskinesia (TD). These drugs are relatively safe and appropriate for
long-term usage in patients with TD. There are not enough evidence-based randomized clinical trials on the applicability of these drugs in children and adolescents; however, some experts prescribe TBZ for children with chorea and chronic tics and dyskinesia, who are refractory to conventional therapies.

Acknowledgement
None.

Author’s contribution
Ali Nikkhah is the corresponding author and designed this article and wrote the manuscript.

Conflict of Interest
The author declares that there is no conflict of interest.

References
1. Sanger TD, Chen D, Fehlings SL, Hallett M, Lang AE, Mink JW, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010; 25(11):1538-49.
2. Nikkhah A, Karimzadeh P, Taghdiri MM, et al. Hyperkinetic Movement Disorders in Children: A Brief Review. Iran J Child Neurol. Spring 2019; 13(2): 7-16.
3. Andrew Billnitzer1 & Joseph Jankovic, 2020 Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments
4. Sreeram V, Shagufta SH, Kagadkar F. Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management. Cureus 2019; 11(8): e5471.
5. Aquino CCH, Lang AE: Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord. 2014, 20:113-7.
6. Paleacu D. Tetrabenazine in the treatment of Huntington’s disease. Neuropsychiatr Dis Treat. 2007; 3:545–51.
7. Laszlo Szpisjak, Andras Salamon, Denes Zadori, Peter Klivenyi & Laszlo Vecse, 2019 Expert Opinion on Pharmacotherapy Selecting dopamine depleters for hyperkinetic movement disorders: how do we choose
8. Witter DP, Holbert RC, Suryadevara U: Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients. Expert Opin Pharmacother. 2017, 18:965-72.
9. Jankovic J: Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016, 17:2461-70.
10. Frank S. Tetrabenazine: The first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat. 2010; 6:657–65.
11. Yero T, Rey JA. Tetrabenazine (Xenazine), an FDA-Approved Treatment Option for Huntington’s Disease-Related Chorea. P T. 2008; 33:690–4.
12. Samay Jain, Paul E. Greene, Steven J. Frucht. Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Movement Disorder Society, 2006 Nov;21(11):1966-72.
13. Linda H Poon , Gail A Kang, Audrey J Lee. Role of tetrabenazine for Huntington’s disease-associated chorea. Ann Pharmacother 2010 Jun; 44(6):1080-9.
14. Miguel R, Mendoca MD, Barbosa R, et al. Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study. Ther Adv Neurol Disord 2017; Vol. 10(2) 81-90.
15. Jankovic, J. and Clarence-Smith, K.
Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother 2011; 11: 1509–1523.

16. Jimenez-Shahed, J. and Jankovic, J. Tetrabenazine for treatment of chorea associated with Huntington disease. Expert Opin Orphan Drugs 2013; 1:423–436.

17. Jankovic J, Glaze DG, Frost JD Jr. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette’s syndrome. Neurology.1984;34:688–92

18. Frank, S. Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group TETRA-HD Investigators Huntington study group. BMC Neurol 2009; 9:62–72.

19. Zaki SA, Lad V, Shanbag P. Quadriaparesis and dysarthria due to tetrabenazine therapy in a child with rheumatic chorea. Indian J Pharmacol. 2011 Sep; 43(5):601-2.

20. Geschwind MD, Paras N. Deutetrabenazine for treatment of chorea in Huntington disease. JAMA 2016; 316:33-35.

21. Touma KTB and Scarff JR. Valbenazine and deutetrabenazine for tardive dyskinesia. Innov Clin Neurosci 2018; 15: 13–16.

22. Frank S, Testa CM, Stamler D, et al.: Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016, 316:40-50.

23. Fernandez HH, Factor SA, Hauser RA, et al.: Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017, 88:2003-10.

24. Anderson KE, Stamler D, Davis MD, et al.: Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017, 4:595-604.

25. Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, Stamler D. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (NY).2016; 6:422.

26. Quezada J, Coffman K A. Current Approaches and New Developments in the Pharmacological Management of Tourette syndrome. CNS Drugs. 2018 Jan; 32(1):33-45.

27. Hauser RA, Factor SA, Marder SR, et al.: KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017, 174:476-84.

28. Factor SA, Remington G, Comella CL, et al.: The effects of valbenazine in participants with tardive dyskinesia: Results of the 1-year KINECT 3 extension study. J Clin Psychiat. 2017, 78:1344-50.

29. Müller T: Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Inv Drug. 2015, 24: 737-742.

30. Martino D, Pringsheim TM. Tourette syndrome and other chronic tic disorders: an update on clinical management. Expert Rev Neurother 2018; 18(2):125–137.

31. Niemann N, Jankovic J. Real-World Experience with VMAT2 Inhibitors. Clin Neuropharmacol 2019; 42(2):37-41.